Table:
| Year Ended December 31, |  |  |
| --- | --- | --- |
|  | 2019 | 2018 |
| Supplemental disclosure of cash flow information |  |  |
| Income taxes paid | $318 | $15 |
| Interest paid | $5,909 | $5,885 |
| Interest received | — | 13 |
| Noncash investing and financing activities |  |  |
| Purchases of property and equipment (including internal use software) | 1,068 | 529 |
| Assignment of NantHealth Labs (see Note 20) | — | 8,956 |
Paragraphs:
NantHealth, Inc
Consolidated Statements of Cash Flows (Continued)
(Dollars in thousands)
(1) Cash and cash equivalents included restricted cash of $1,136, $1,136, and $350 at December 31, 2019, 2018, and 2017 included in other assets, respectively. Restricted cash consists of funds that are contractually restricted as to usage or withdrawal related to the Company's security deposits in the form of standby letters of credit for leased facilities. No amounts have been drawn upon the letters of credit as of December 31, 2019.
The accompanying notes are an integral part of these Consolidated Financial Statements.
Question:
What are the respective restricted cash included in the cash and cash equivalents in 2019 and 2017 respectively?
Answer: $1,136, $350